Answers are grounded in this paper and cite their sources.
Androgenetic alopecia (AGA) is the most common form of hair loss, affecting approximately 21.3% of men and 6% of women in China, with an increasing trend among younger individuals. Currently, finasteride and minoxidil are the only two non-surgical medications approved for the treatment of AGA, but both face limitations in efficacy and safety concerns. Polygoni multiflori radix (PMT) has been traditionally used to treat premature graying and hair loss since ancient times. Its effects align with certain clinical manifestations of modern AGA, leading to extensive recent exploration for its application in AGA prevention and treatment. Compared to other chemical drugs, PMT offers more comprehensive therapeutic effects with a potentially favorable safety profile and acceptable tolerability, making it more readily accepted by patients. This review synthesizes findings from multiple databases to summarize the active components, mechanisms of action, and current applications of PMT in AGA. It provides a reference basis for in-depth research and new drug development regarding the use of PMT in AGA. • Summarizes historical use and current evidence of Polygoni multiflori radix (PMT) for androgenetic alopecia (AGA). • Elucidates PMT’s multi-target, multi-pathway mechanisms in treating androgenetic alopecia. • Identifies key active ingredients (e.g.,TSG,emodin) responsible for its hair-growth promoting effects. • Discusses the successful application of PMT in modern cosmeceuticals and hair care products. • Highlights PMT as a natural alternative to conventional drugs with fewer side effects.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: